The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Medical Instruments & Supplies
Shenzhen Salubris Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.79% CNY31.35
America/New_York / 6 mai 2024 @ 03:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 34 214 mill |
| EPS: | 0.510 |
| P/E: | 61.47 |
| Earnings Date: | Aug 28, 2024 |
| SharesOutstanding: | 1 091.36 mill |
| Avg Daily Volume: | 5.41 mill |
| RATING 2024-05-06 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.71x |
| Company: PE 61.47 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.02x |
| Company: PE 61.47 | industry: PE 60.36 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY12.13 (-61.31%) CNY-19.22 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
CNY 30.88 - 32.72 ( +/- 2.88%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY31.35 (-1.79% ) |
| Volume | 9.30 mill |
| Avg. Vol. | 5.41 mill |
| % of Avg. Vol | 172.09 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 002294.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
002294.SZ
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel bisulfate tablets, as well as bivalirudin and pamidronate disodium injections; recombinant SeV-hFGF2/dF Injection for the treatment of diabetic foot disease; and anti-tumor and orthopedics medicines. The company also provides anti-infection products comprising cefonicid sodium, ceftazidime, ceftriaxone sodium, cefonicid sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium injections, as well as azithromycin dispersible and levetiracetam tablets. In addition, it offers biotechnological drugs, such as recombinant protein and monoclonal antibody drugs. Further, the company is involved in import, licensing-in, and licensing-out medicines for Europe markets. The company was founded in 1998 and is headquartered in Shenzhen, China.